The research hinges on evaluating nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and another novel NAD+ precursor or booster, examining how each modulates circulatory NAD+ concentrations. Using a double-blinded, randomized controlled trial framework, the team assessed longitudinal changes in blood NAD+ metabolites in healthy adult participants. Their comprehensive metabolic profiling revealed stark contrasts between the boosters, not only in their efficacy to elevate plasma NAD+ but also in their downstream impacts on metabolic intermediates and microbial metabolite signatures detected in circulation. These findings challenge the prevailing notion that all NAD+ precursors function interchangeably, shedding light on their unique biochemical footprints within the human body.

One of the study’s most compelling revelations involves the intricate interplay between NAD+ booster supplementation and gut microbiota metabolism. Emerging evidence has implicated the gut microbiome as a critical modulator of host NAD+ homeostasis, with certain bacteria capable of influencing niacin-related pathways. In this study, detailed metabolomic analyses unveiled that supplementation with different NAD+ boosters triggered distinct shifts in microbial-derived metabolites detectable in the bloodstream. This suggests that NAD+ precursors not only act as direct metabolic substrates but may also engender systemic effects by modulating microbial ecology and function within the gastrointestinal tract. Such insights open new avenues for understanding host-microbe co-metabolism in the context of aging and metabolic disease.

Delving deeper into the pharmacokinetic profiles of these compounds, the investigators observed variability in absorption kinetics and bioavailability that may explain their disparate systemic effects. While NMN tends to undergo rapid conversion prior to systemic circulation, NR showed a distinct absorption pattern conducive to more sustained NAD+ elevation. These kinetic variations were evidenced by differential peak plasma concentrations and metabolite half-lives, findings that underscore the importance of compound-specific pharmacodynamics in designing NAD+ augmentation strategies. Moreover, this pharmacokinetic heterogeneity translated into varying modulation of downstream sirtuin activity and DNA repair enzyme systems, critical determinants of cellular resilience and longevity.

In addition to systemic NAD+ dynamics, the study focused attention on the molecular signatures in peripheral blood mononuclear cells (PBMCs) as a window into cellular NAD+ metabolism and signaling. Using high-resolution mass spectrometry and transcriptomic analyses, the researchers demonstrated that NAD+ boosters elicited divergent gene expression patterns related to oxidative stress responses, inflammatory pathways, and mitochondrial biogenesis. This molecular heterogeneity suggests that the choice of NAD+ supplement may have far-reaching implications beyond merely boosting coenzyme concentrations, impacting cellular health programs that govern metabolic stability and immune function. These nuanced insights reinforce the notion that targeted NAD+ interventions must be personalized to optimize healthspan.

The impact on immune cell metabolism was especially notable, as certain NAD+ boosters preferentially enhanced mitochondrial oxidative phosphorylation and ATP production in T cells, while others modulated glycolytic flux. These mechanistic distinctions could underpin differences in the immunomodulatory potential of each NAD+ enhancer, with profound implications for managing age-related immunosenescence and inflammatory diseases. The authors emphasize that identifying which NAD+ precursors best support immune metabolic reprogramming may pave the way for adjunct therapies in immunometabolic disorders, offering a targeted approach to bolster host defenses in aging populations.

Furthermore, the trial included advanced microbiome sequencing to track changes in gut bacterial communities in response to supplementation. Remarkably, specific taxa known to participate in niacin metabolism exhibited altered abundance profiles depending on the NAD+ booster administered. This supports a feedback loop where NAD+ precursors not only serve as substrates for host metabolism but also actively shape the microbial milieu, which in turn modulates systemic NAD+ precursor availability. Such bidirectional host-microbiome interactions hold promise for therapeutic manipulation, potentially leveraging microbiota-targeted interventions to synergize with metabolic boosters and enhance efficacy.

An especially intriguing aspect of the investigation was the identification of unique circulatory metabolite signatures associated with each NAD+ compound, illuminating distinct metabolic pathways preferentially engaged. For instance, NR supplementation led to elevated plasma levels of nicotinic acid derivatives, linking to the Preiss-Handler pathway, while NMN administration showed enhanced nicotinamide-related metabolites consistent with salvage pathway activation. These biochemical distinctions have important ramifications for clinical applications, as different metabolic routes may confer varied benefits or side effects, influencing long-term safety and effectiveness.

The study’s comprehensive metabolomic approach also revealed how NAD+ boosters variably affected systemic redox balance. By quantifying ratios of NAD+/NADH and associated cofactors, the authors demonstrated that certain boosters more effectively restored oxidative homeostasis, thus potentially mitigating oxidative stress—a key contributor to aging and chronic disease pathogenesis. This redox modulation aligns with improved mitochondrial function and reduced cellular senescence markers, corroborating the multifaceted benefits of optimized NAD+ metabolism. These findings integrate into a broader framework linking metabolic control, oxidative stress, and tissue integrity, emphasizing the therapeutic potential of tailored NAD+ augmentation.

Critically, the safety profiles of the three NAD+ enhancers were systematically evaluated, confirming excellent tolerability and minimal adverse effects even with chronic administration. Nonetheless, subtle differences emerged in biochemical parameters such as liver enzyme levels and plasma inflammatory markers, suggesting that individualized dosing and careful monitoring remain essential in clinical contexts. The authors advocate for further long-term studies to elucidate the risk-benefit balance, particularly in vulnerable populations with metabolic or inflammatory comorbidities. This cautionary note underscores the complexity of intervening in core metabolic pathways and the necessity of a precision medicine approach.

The research’s translational potential is vast, proposing a paradigm shift in how NAD+ boosting therapies are conceived and applied. By delineating the unique systemic and microbial metabolic impacts of different precursors, the study lays the groundwork for personalized metabolic medicine where interventions are tailored to individual metabolic phenotypes and microbiome profiles. This precision could maximize therapeutic efficacy, minimize off-target effects, and harness host-microbiome synergies to promote healthy aging. The insights presented resonate deeply with the burgeoning field of metabolic supplementation, offering a blueprint for next-generation NAD+ targeted therapeutics.

Moreover, the authors propose that combining NAD+ boosters with specific prebiotics or probiotics could amplify their benefits by modulating gut microbiota composition favorably. Such combinatorial strategies may potentiate NAD+ metabolism, enhance mitochondrial function, and reinforce systemic metabolic resilience. This integrative approach leverages emerging knowledge on host-microbe co-metabolism, representing a promising frontier in nutritional and pharmacological interventions aimed at improving human healthspan.

Collectively, this landmark study offers a nuanced and comprehensive perspective on NAD+ biology, emphasizing that not all supplementation approaches are created equal. The differential effects of NR, NMN, and the third booster on circulatory NAD+, immune cell metabolism, microbial ecology, and systemic redox balance demand a reevaluation of current therapeutic guidelines. As interest in NAD+ enhancement accelerates in both clinical and consumer wellness sectors, these findings provide critical evidence to inform safe and effective use, steering the field towards precision-targeted metabolic interventions.

In conclusion, the meticulous characterization of how distinct NAD+ boosters alter human physiology and microbial metabolism illuminates previously underappreciated complexities in NAD+ biology. This study exemplifies the sophisticated interplay between metabolic substrates, host cellular function, and the gut microbiome, highlighting avenues for personalized medicine. As aging and metabolic diseases impose growing burdens globally, interventions targeting fundamental metabolic pathways—such as those explored in this research—hold transformative promise to enhance healthspan and mitigate disease risk. Future investigations building on these insights will undoubtedly refine therapeutic strategies, propelling the quest for optimized longevity.

Subject of Research: The effects of different NAD+ boosters on circulatory NAD+ levels and microbial metabolism in humans.

Article Title: The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans.

Article References:
Christen, S., Redeuil, K., Goulet, L. et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01421-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01421-8

Radiation therapy plays a vital role in cancer treatment. However, its effects on normal tissues are a significant concern. The intestinal epithelium, which serves as a frontline barrier against pathogens and is crucial for nutrient absorption, often suffers severe damage due to radiation. This damage manifests as inflammation, edema, and, in severe cases, necrosis. Such reactions can lead to dire complications, including debilitating gastrointestinal symptoms and detrimental impacts on patient quality of life. As a result, protecting the intestinal lining during radiation therapy emerges as a crucial objective in oncological care.

The authors of the study turned their attention toward gasdermin E, a protein involved in pyroptosis – a form of programmed cell death that is distinct from apoptosis. Pyroptosis is characterized by the formation of pores in the cellular membrane, leading to cell lysis and the release of inflammatory cytokines. This process is beneficial in some contexts, such as infectious diseases, but becomes detrimental in the setting of tissue damage, like that induced by radiation. By targeting pyroptosis, particularly gasdermin E-mediated pathways, the team sought to identify a therapeutic strategy that could minimize collateral damage while preserving the integrity of intestinal cells.

Nicotinamide riboside has gained attention for its role as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme critical for various metabolic processes and cellular repair mechanisms. By augmenting NAD+ levels, NR has been shown to enhance mitochondrial function and promote cellular resilience against stressors. These properties position NR as a promising candidate for reducing tissue damage in scenarios where cells are subjected to inflammatory and oxidative stresses.

The research led by Zhou and colleagues meticulously demonstrated that treatment with NR significantly reduced markers of intestinal injury in preclinical models exposed to ionizing radiation. The investigators employed various in vitro and in vivo models to carefully evaluate the biochemical pathways activated by NR. They found that NR application resulted in lowered activation of gasdermin E, implying that the compound effectively curbed pyroptosis within intestinal epithelial cells. This elegant mechanism underscores the unique ability of NR to navigate cellular responses to radiation exposure.

One of the most compelling aspects of this study was the observed reduction in pro-inflammatory cytokines following NR treatment. Cytokines are messengers in the immune system, and their excess production can aggravate tissue damage and prolong inflammation, creating a vicious cycle of cellular injury. By mitigating the release of these cytokines, NR does not just protect intestinal cells but also potentially alleviates the overarching inflammatory response, thus paving the way for improved recovery.

Interestingly, the results indicated that NR administration led to enhanced intestinal barrier function. This critical outcome has vast implications for patient management in clinical settings. A robust intestinal barrier prevents the translocation of bacteria and toxins from the gut into systemic circulation, which can provoke septic complications in vulnerable patients. By reinforcing this barrier, NR may hold the key to reducing both local and systemic complications associated with radiation therapy.

The potential applications of NR extend beyond radiation therapy. Considering its mode of action, the findings may provide insights into developing therapies for other conditions associated with intestinal injury, including inflammatory bowel diseases and even acute pancreatitis. The versatility of NR as a protective agent suggests it could play a role in a broader therapeutic context, thereby appealing to a wide range of patients suffering from gastrointestinal distress.

As the medical community continues to explore NR’s therapeutic window, further studies will be vital in optimizing dosages and administration routes. Understanding the pharmacokinetics of NR and potential interactions with existing treatments will be crucial to its successful integration into clinical practice. Early-phase trials could rapidly follow, as there is a strong impetus for finding interventions to improve outcomes during chemotherapy and radiation therapies.

In conclusion, the research conducted by Zhou and his team provides a promising avenue for the use of nicotinamide riboside as a protective agent against radiation-induced intestinal injury. Through its elegant action on gasdermin E-mediated pyroptosis, NR opens doors to enhanced patient care in oncology. The drive towards translational research in this domain offers a glimmer of hope for patients undergoing radiation therapy, hinting at improved quality of life and therapeutic outcomes in the future.

As we await further investigations into the clinical feasibility of NR, the scientific community can celebrate a vital step towards innovative strategies in cancer treatment, where protection of the intestinal barrier could lead to a paradigm shift in patient care. The disruptions caused by radiation therapy may soon be alleviated by the harnessing of natural compounds such as nicotinamide riboside, providing renewed optimism for both patients and physicians alike.

Ultimately, the advances in our understanding of cellular responses to radiation injury and the potential for targeted interventions highlight a critical era in medical science where nutrition and molecular biology intersect to yield unexpected treatments. These insights underscore the importance of continued investment in research that aims to unlock the healing promises of the molecules within our reach.

Subject of Research: Radiation-induced intestinal injury and protective agents

Article Title: Nicotinamide riboside attenuates radiation-induced intestinal injury by suppressing gasdermin E-mediated pyroptosis in intestinal epithelial cells

Article References:

Zhou, Q., Liu, L., Lin, X. et al. Nicotinamide riboside attenuates radiation-induced intestinal injury by suppressing gasdermin E-mediated pyroptosis in intestinal epithelial cells. J Transl Med 23, 1126 (2025). https://doi.org/10.1186/s12967-025-07012-1

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07012-1

Keywords: Nicotinamide riboside, radiation therapy, intestinal injury, gasdermin E, pyroptosis, cytokines, intestinal barrier.

The allure of NAD⁺ precursors as anti-ageing interventions originates from their capacity to replenish cellular NAD⁺ pools, thereby ostensibly restoring metabolic balance and enhancing cellular repair mechanisms. In rodent models, supplementation with compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has been associated with improvements in mitochondrial function, cognitive performance, and lifespan extension. However, human clinical trials investigating the efficacy of NAD⁺ precursor supplements have largely produced modest or equivocal outcomes. These discrepancies underscore the complexity of NAD⁺ metabolism in humans and hint at nuanced, tissue-specific dynamics that diverge from those observed in animal models.

Critically, the quantification of NAD⁺ levels in human tissues remains a formidable challenge, constrained by the invasiveness of sampling techniques and the paucity of longitudinal data. Unlike rodents, where tissue biopsies can be systematically obtained and analyzed, human studies often rely on peripheral blood or limited tissue biopsies, which may not fully capture the systemic and local variations of NAD⁺ status. Moreover, the heterogeneity of human populations, influenced by genetics, lifestyle, diet, and comorbidities, adds layers of variability challenging the interpretation of NAD⁺ dynamics with ageing.

Emerging evidence tentatively confirms an age-associated decline in NAD⁺ in select human tissues such as skeletal muscle and brain, yet this decline is neither universal nor consistent across all studies. The complexity deepens when considering NAD⁺ precursor supplementation, which has shown variable efficacy across different tissues. For instance, some studies report increased NAD⁺ concentrations in skeletal muscle or blood following NR or NMN administration, while others detect minimal or transient changes. This variability raises pivotal questions about the bioavailability, tissue targeting, and metabolic fate of supplemented precursors in humans.

At the molecular level, NAD⁺ functions both as a substrate for enzymes like sirtuins and poly(ADP-ribose) polymerases (PARPs) and as a redox carrier shuttling electrons during metabolic reactions. The balance between NAD⁺ synthesis, consumption, and recycling governs cellular energetic and stress responses. Ageing disrupts this balance by elevating NAD⁺ consumption through DNA damage and chronic inflammation, simultaneously impairing biosynthetic pathways. Understanding how these opposing forces influence NAD⁺ pools in distinct tissues remains fundamental for devising effective therapeutic strategies.

In addition to systemic factors, intracellular compartmentalization of NAD⁺ adds complexity. NAD⁺ pools exist in cytosolic, nuclear, and mitochondrial compartments, each fulfilling unique roles. The crosstalk between these pools and their regulation may vary with age and disease states, potentially explaining the differential responses observed upon supplementation. Current analytical methods often measure total NAD⁺ without resolving compartment-specific dynamics, limiting mechanistic insights.

Clinical trials to date have predominantly focused on relatively healthy older adults, often employing short-duration supplementation and limited dosing regimens. Such parameters may be insufficient to elicit measurable biological effects, especially considering age-related declines in NAD⁺ biosynthetic efficiency and possible alterations in precursor uptake or metabolism. Future studies will need to explore optimized dosing, duration, and combination therapies, as well as stratify participants based on metabolic and molecular biomarkers to identify responders versus non-responders.

Beyond ageing, NAD⁺ metabolism intersects intimately with various pathological conditions, including metabolic syndrome, neurodegenerative diseases, and cardiovascular disorders. The interplay between disease processes and NAD⁺ homeostasis may complicate interpretation of supplementation outcomes. For example, chronic diseases may impose heightened NAD⁺ consumption or impair salvage pathways, necessitating tailored therapeutic approaches. Personalized medicine frameworks incorporating NAD⁺ metabolism profiling could enhance intervention efficacy.

Furthermore, the safety profile of long-term NAD⁺ precursor supplementation warrants thorough investigation. While generally well-tolerated in short-term trials, potential off-target effects, metabolic imbalances, or perturbations of cellular signaling pathways must be carefully scrutinized in larger and extended studies. Regulatory oversight and standardized protocols will be crucial as these compounds gain popularity as nutraceuticals.

Technological advancements in mass spectrometry, imaging, and omics methodologies promise to shed light on the intricate landscape of NAD⁺ metabolism across tissues and disease states. These tools enable quantification of NAD⁺ and related metabolites with high spatial and temporal resolution, providing unprecedented opportunities to elucidate mechanisms underlying NAD⁺ dynamics and to refine supplementation strategies.

In sum, the enthusiasm for NAD⁺ precursor supplementation as a panacea for ageing-related decline is tempered by a nascent and fragmented clinical evidence base. Bridging the translational gap from rodent models to humans demands a concerted effort to conduct comprehensive, multisystem clinical studies integrating molecular, cellular, and physiological endpoints. Such endeavors will clarify the true potential and limitations of NAD⁺-targeted therapies in promoting healthy human ageing.

Ultimately, advancing this field hinges on embracing the biological complexity of NAD⁺ metabolism and recognizing the multifactorial nature of ageing. Integrative research initiatives that factor in genetics, lifestyle, metabolic health, and environmental exposures are essential to devise precision interventions. As the scientific community accelerates towards these goals, NAD⁺ precursor supplementation remains a compelling yet evolving frontier in the quest to decipher and modulate the ageing process.

Subject of Research:
Nicotinamide adenine dinucleotide (NAD⁺) metabolism and its modulation through precursor supplementation in the context of human ageing.

Article Title:
NAD⁺ precursor supplementation in human ageing: clinical evidence and challenges.

Article References:
Vinten, K.T., Trętowicz, M.M., Coskun, E. et al. NAD⁺ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01387-7

Image Credits: AI Generated